Accordingly, Barth et al. analyzed a large panel of luminal and basal markers in a series of 156 CIS cases [31], most of them being characterized by the expression of luminal markers, including HER2; such findings were confirmed in a more recent study from the same group [22]. This evidence concerns the gene ERBB2 and in situ carcinoma.